A Japanese health ministry panel on November 28 agreed on a plan to legally require pharma companies to set up…
REGULATORY
Novavax COVID-19 Jab OK’ed for 1st to 3rd Shot Use under Free Program
A Japanese health ministry panel on April 27 agreed to incorporate Novavax’s COVID-19 vaccine Nuvaxovid into Japan’s free emergency inoculation program for assumed use for the first to third inoculations. The jab had won regulatory approval earlier this month. Under…
To read the full story
Related Article
- Nuvaxovid Gets Label Update to Allow Primary Inoculations in Ages 12 and Older
July 21, 2022
- Japan Plans to Lower Minimum Age for Novavax Jab to 12
July 19, 2022
- Novavax Vaccine Officially Added to Japan’s Free COVID-19 Inoculation Program
May 26, 2022
- Japan Approves Novavax’s COVID-19 Vaccine; Distribution to Start in Late May
April 19, 2022
- Novavax COVID-19 Vaccine Clears MHLW Panel, Approval Expected Soon
April 19, 2022
- Japan to Start Distributing Novavax Jab from Late May, If Approved
April 7, 2022
- Novavax’s COVID-19 Vaccine Up for PAFSC Review on Regular Pathway
April 5, 2022
- Japan Secures 18 Million Extra Doses of Moderna Vaccines
December 27, 2021
- Novavax’s COVID-19 Vaccine Filed in Japan: Takeda
December 16, 2021
- Japan Strikes Deal for 150 Million Novavax Vaccine Doses, Supply Could Start Early Next Year
September 7, 2021
- Japan Secures Enough Doses for Booster Shots Next Year: Minister
August 18, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Takeda Pairs with Novavax to Roll Out Coronavirus Vaccine in Japan, Wins 30 Billion Yen in Govt Funding
August 11, 2020
REGULATORY
- LDP Members Urge Ministers to End “Mechanical” Off-Year Price Cuts
December 27, 2024
- Quality Assurance and Lag/Loss Fight to Form Pillars of PMD Act Amendment
December 27, 2024
- Japan to Set Up Fund to Spur Generic Shakeup; CEA, Market Expansion Re-Pricing on Agenda
December 26, 2024
- Gist of FY2025 Drug Price Revision
December 26, 2024
- Chuikyo OKs Outline of FY2025 Off-Year Drug Price Revision
December 26, 2024
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
Takeda Pharmaceutical’s overseas sales ratio has reached 90.9%, exceeding 90% for the first time though only in the first half…
In a recent conversation with James Feliciano, former president of AbbVie Japan, we delved into the intricacies of leadership in the Japanese pharmaceutical industry. Feliciano, a seasoned industry veteran, shared valuable insights into his experiences, challenges, and successes.Navigating the Abbott…
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…